Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
Reason given: Slow patient enrollment and lack of financial support
Key facts
- Where
- Gongyi, Kaifeng, Xinxiang, Xinzheng, Xuchang, and Zhengzhou, ChinaSee the 6 sites
- Phase
- Phase 4
Where in China
- The People's Hospital of GongyiGongyi, ChinaNo longer taking part
- Kaifeng Central HospitalKaifeng, ChinaNo longer taking part
- The People's Hospital of ChangyuanXinxiang, ChinaNo longer taking part
- Hopeshine Minsheng Hospital of XinzhengXinzheng, ChinaNo longer taking part
- The People's Hospital of XuchangXuchang, ChinaNo longer taking part
- Fuwai Central China Cardiovascular HospitalZhengzhou, ChinaNo longer taking part
Trial details
- Who runs it
- Henan Institute of Cardiovascular Epidemiology
- Trial code
- NCT05613426
- Record updated
- 22 May 2026
- Original description
For patients with anterior ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), whether early application of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors to rapidly reduce low-density lipoprotein cholesterol (LDL-C) before PCI could effectively inhibit left ventricular remodeling has been rarely reported. The aim of this study was to investigate the effect of early application of PCSK9 inhibitors Evolocumab to rapidly reduce LDL-C levels before primary PCI treatment on left ventricular remodeling in STEMI patients.Read full original descriptionShow less
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical Trial
For patients with anterior ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), whether early application of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors to rapidly reduce low-density lipoprotein cholesterol (LDL-C) before PCI could effectively inhibit left ventricular remodeling has been rarely reported. The aim of this study was to investigate the effect of early application of PCSK9 inhibitors Evolocumab to rapidly reduce LDL-C levels before primary PCI treatment on left ventricular remodeling in STEMI patients.
Eligible patients were randomly randomized 1:1:1 to one of the following three groups immediately after enrollment: (1) Intensive statin group: rosuvastatin 20 mg per day, in addition to usual therapy; (2) Combined intensive statin and PCSK9 inhibitor group: rosuvastatin 20 mg per day and subcutaneous injection of evolocumab 140 mg twice a month, for at least 3 months, and preferably 6 months; (3) PCSK9 inhibitor alone group: subcutaneous injection of evolocumab 140 mg, twice a month for at least 3 months and preferably 6 months.
Inclusion: Age 18-75 years; Persistent chest pain or chest discomfort; Onset within 12 hours; ST-segment elevation ≥0.1 millivolt in two adjacent precordial leads, or a new-onset left bundle branch block with dynamic changes; Primary PCI is planned.
Exclusion: Contraindications to Statins or PCSK9 inhibitors; Prior intravenous thrombolytic therapy; Prior use of Statins, PCSK9 inhibitors or Ezetimibe; Prior chronic heart failure; Acute heart failure or pulmonary edema; Severe hepatic and renal insufficiency (alanine aminotransferase ≥5 upper limit of normal; estimated glomerular filtration rate <30ml/min/1.73m2, or on dialysis); Definite mechanical complications (including ventricular septal perforation, or rupture of the Papillary tendon bundle, or rupture of the left ventricular free wall); Malignant arrhythmias that are difficult to control with drugs; Severe chronic obstructive pulmonary disease or respiratory failure; Severe infection; Neurological disorders; Bleeding history of cerebrovascular, gastrointestinal, respiratory, urinary or other organs within the last month; Active bleeding or bleeding diatheses; Malignant tumors or other pathophysiological conditions with an expected survival time of less than 1 year; Cardiogenic shock; Prolonged (> 20 minutes) cardiopulmonary resuscitation; Use of anticoagulants; Pregnant or lactating women.